| InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript |
InspireMD, Inc. (NASDAQ:NSPR ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Webb Campbell – Gilmartin Group LLC Marvin Slosman – Chief Executive Officer Craig Shore – Chief Financial Officer Shane Gleason – Chief Commercial Officer Conference Call Participants Adam Maeder – Piper Sandler Frank Takkinen – Lake Street Capital Operator Good morning, and welcome to InspireMD's First Quarter 2025 Earnings Conference call. [Operator Instructions] We will facilitating a question-and-answer session towards the end of today's call. |
seekingalpha.com |
2025-05-09 16:07:00 |
Czytaj oryginał (ang.) |
| InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates |
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. |
zacks.com |
2025-05-09 13:15:37 |
Czytaj oryginał (ang.) |
| InspireMD Reports First Quarter 2025 Financial Results |
Management to host investor conference call today, May 9th, at 8:30am ET Management to host investor conference call today, May 9th, at 8:30am ET |
globenewswire.com |
2025-05-09 11:00:00 |
Czytaj oryginał (ang.) |
| InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference |
MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the Bank of America 2025 Healthcare Conference on Wednesday, May 14, 2025, at 1:15PM Eastern Time / 10:15AM Pacific Time. |
globenewswire.com |
2025-04-30 13:00:00 |
Czytaj oryginał (ang.) |
| InspireMD to Announce First Quarter 2025 Financial Results |
MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. |
globenewswire.com |
2025-04-25 13:00:00 |
Czytaj oryginał (ang.) |
| InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to 11 new non-executive employees in the aggregate amount of 299,398 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of April 1, 2025, as an inducement material to the employees and the director entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-08 13:00:00 |
Czytaj oryginał (ang.) |
| InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference |
MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 90 days on the “News & Events” section of the company's website at: https://www.inspiremd.com/en/events/ About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. |
globenewswire.com |
2025-03-26 11:00:00 |
Czytaj oryginał (ang.) |
| InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript |
NSPR (NASDAQ:NSPR ) Q4 2024 Earnings Conference Call March 12, 2025 8:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Webb Campbell - IR, Gilmartin Group Conference Call Participants Adam Maeder - Piper Sandler Frank Takkinen - Lake Street Capital Markets Richard Nesbitt - InspireMD Operator Hello and welcome to InspireMD's fourth quarter 2024 earnings conference call. [Operator instructions]. |
seekingalpha.com |
2025-03-12 15:53:41 |
Czytaj oryginał (ang.) |
| InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates |
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago. |
zacks.com |
2025-03-12 11:10:25 |
Czytaj oryginał (ang.) |
| InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results |
MIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. ahead of an anticipated first half 2025 approval Announced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures Established headquarters in Miami, Florida, to optimally support the anticipated U.S. commercial launch of CGuard Prime in the first half of 2025, if approved Achieved quarterly revenue and unit records of $1.95M and 3.5K respectively in served markets Marvin Slosman, CEO of InspireMD, commented: “2024 was a year of tremendous progress at InspireMD. |
globenewswire.com |
2025-03-12 09:00:00 |
Czytaj oryginał (ang.) |
| InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results |
MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. |
globenewswire.com |
2025-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to six new non-executive employees in the aggregate amount of 138,442 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of February 5, 2025, as an inducement material to the employees and the director entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures |
TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid stenosis, and NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, today announced that, pursuant to a previously announced strategic outsourcing partnership, the companies are working together to conduct the CGUARDIANS II pivotal study of InspireMD's CGuard Prime™ 80 cm carotid stent system for use in Transcarotid Artery Revascularization (TCAR) procedures. |
globenewswire.com |
2025-02-13 09:00:00 |
Czytaj oryginał (ang.) |
| InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MIAMI, Feb. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one new non-executive employee in the amount of 18,000 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of January 7, 2025, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-04 09:00:00 |
Czytaj oryginał (ang.) |
| NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study |
InspireMD announces the first patient enrolment in the CGUARDIANS II clinical trial. |
zacks.com |
2024-12-11 15:20:21 |
Czytaj oryginał (ang.) |
| InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) |
Study represents a significant step forward in Company's mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions Study represents a significant step forward in Company's mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions |
globenewswire.com |
2024-12-09 09:00:00 |
Czytaj oryginał (ang.) |
| InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors |
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. |
globenewswire.com |
2024-11-25 18:05:00 |
Czytaj oryginał (ang.) |
| InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript |
InspireMD, Inc. (NASDAQ:NSPR ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Chuck Padala - IR, Life Advisors Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Conference Call Participants Adam Maeder - Piper Sandler Operator Good day, everyone, and welcome to the InspireMD Third Quarter 2024 Earnings Call. Currently, all participants are in a listen-only mod e. |
seekingalpha.com |
2024-11-12 12:20:28 |
Czytaj oryginał (ang.) |
| InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates |
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.15 per share a year ago. |
zacks.com |
2024-11-12 11:26:08 |
Czytaj oryginał (ang.) |
| InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-11-08 19:30:00 |
Czytaj oryginał (ang.) |
| InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System |
MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of its global headquarters in Miami, Florida. The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved. |
globenewswire.com |
2024-10-15 11:00:00 |
Czytaj oryginał (ang.) |
| InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent |
NSPR gains premarket approval for its CGuard Prime carotid stent system for use in United States for treating carotid artery stenosis. |
zacks.com |
2024-10-10 14:45:18 |
Czytaj oryginał (ang.) |
| InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System |
MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures. |
globenewswire.com |
2024-10-07 11:00:00 |
Czytaj oryginał (ang.) |
| NSPR Stock Declines Despite PMA Application Submission for CGuard |
InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS. |
zacks.com |
2024-09-17 16:41:17 |
Czytaj oryginał (ang.) |
| InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System |
PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May |
globenewswire.com |
2024-09-16 11:00:00 |
Czytaj oryginał (ang.) |
| InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates |
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago. |
zacks.com |
2024-08-06 14:25:30 |
Czytaj oryginał (ang.) |
| InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update |
- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial – |
globenewswire.com |
2024-08-06 12:09:00 |
Czytaj oryginał (ang.) |
| InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment |
CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials CREST-2 included 23 cases implanted with CGuard TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today congratulated the lead investigators on the completion of enrollment in the CREST-2 (Carotid Revascularization Endarterectomy or Stenting Trial) clinical trials. The CGuard carotid stent, utilizing its proprietary MicroNet™ mesh, was included as a device option for stenting in the CREST-2 trials following FDA approval of InspireMD's Investigational Device Exemption (IDE) supplement application in February 2022. |
globenewswire.com |
2024-08-05 11:00:00 |
Czytaj oryginał (ang.) |
| InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th |
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2024 financial results on Tuesday, August 6th, before the financial markets open. |
globenewswire.com |
2024-07-30 11:00:00 |
Czytaj oryginał (ang.) |
| InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024 |
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial |
globenewswire.com |
2024-05-28 12:53:00 |
Czytaj oryginał (ang.) |
| InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript |
InspireMD Inc. (NASDAQ:NSPR ) Q1 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Chuck Padala - Managing Director Marvin Slosman - President, CEO & Director Craig Shore - CFO, Chief Administrative Officer, Secretary & Treasurer Conference Call Participants Adam Maeder - Piper Sandler Operator Greetings, and welcome to the InspireMD First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-14 14:50:25 |
Czytaj oryginał (ang.) |
| InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update |
- Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - |
globenewswire.com |
2024-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th |
TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open. Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments. |
globenewswire.com |
2024-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference |
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024. |
globenewswire.com |
2024-04-03 12:59:00 |
Czytaj oryginał (ang.) |